Cabometyx (Cabozantinib S-Malate) Patent Expiration, LOE Window & CMS Spending
Cabometyx (Cabozantinib S-Malate) by Exelixis: FDA Orange Book core substance LOE 2030-10-08 (last listed 2033-07-09), 1 AB generics, $1.35B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Exelixis |
| FDA Application & Pathway | N208692 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-10-08 |
| Last Listed Patent or Exclusivity Date | 2033-07-09 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $1.35B |
| 2024 Medicare Part D Spend | $1.22B |
| 2024 Medicaid Spend | $128.7M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 18.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Exelixis across sibling Meru public-data platforms.